KALA BIO, Inc. KALA
Set alert
0.17 USD 0.00 +1.03%
At close · Nov 2
0.17 0.00 +1.56%
After hours · Nov 2, 4:00 PM ET
0.1664 Day range 0.1799
0.115 52-week range 95.50
- YTD
- -99.40%
- 1 year
- -99.57%
- Open
- 0.17
- Prev close
- 0.1655
- Mkt cap
- 3.23M
- Vol
- 139.00K
- Avg vol
- 1.51M
- EPS
- -10.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1664
- High
- 0.1799
- Forward P/E
- -0.90
- Beta
- -2.14
- Short ratio
- 1.91
- Inst. own
- 48.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.42
- 200-d avg
- 6.50
- 1y target
- 15.00
5Y chart
Events in this range
- Aug 26, 2022Split: 2 for 1
- Oct 21, 2022Split: 1 for 50
- Aug 4, 2023Earnings: -4.36; estimate -3.19; surprise -36.68%
- Nov 13, 2023Earnings: -3.41; estimate -2.15; surprise -58.6%
- Nov 17, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Mar 29, 2024Earnings: -3.18; estimate -3.62; surprise 12.15%
- Apr 1, 2024Rating: Oppenheimer · Outperform → Outperform
- Apr 2, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 14, 2024Earnings: -4.2; estimate -2.89; surprise -45.33%
- May 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 6, 2024Earnings: -3.16; estimate -4.41; surprise 28.34%
- Aug 19, 2024Rating: Oppenheimer · Outperform → Outperform
- Nov 12, 2024Earnings: -1.93; estimate -2.43; surprise 20.58%
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 11, 2026Split: 1 for 50
Signals (73)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| RSI: Overbought | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
Newest 20 of 73.
Key statistics
- Market cap
- 27.66M
- Enterprise value
- 15.27M
- Trailing P/E
- 0.00
- Forward P/E
- -0.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.21
- EPS (TTM)
- -11.67
- Beta
- -2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.51M
- Total cash
- 54.20M
- Total debt
- 36.80M
- Return on equity
- -248.11%
- Shares outstanding
- 4.61M
- Short % of float
- 0.85%
- 50-day average
- 6.42
- 200-day average
- 6.50
Analyst view
Consensus: none
Price target (mean) 15.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.47.
Financials — quick view
KALA Revenue — quarterly 0
KALA Net income — quarterly -1.58M
KALA EPS — quarterly -21.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -2.43 | -1.93 | +0.50 | +20.58% |
| Aug 6, 2024 | Jun 1, 2024 | -4.41 | -3.16 | +1.25 | +28.34% |
| May 14, 2024 | Mar 1, 2024 | -2.89 | -4.20 | -1.31 | -45.33% |
| Mar 29, 2024 | Dec 1, 2023 | -3.62 | -3.18 | +0.44 | +12.15% |
| Nov 13, 2023 | Sep 1, 2023 | -2.15 | -3.41 | -1.26 | -58.60% |
| Aug 4, 2023 | Jun 1, 2023 | -3.19 | -4.36 | -1.17 | -36.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Nov 17, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About KALA BIO, Inc.
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kalarx.com
News
Your note
Sign in to keep a note on KALA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAZEMORE TODD M | President | Sale | Jun 25, 2024 | 22,385 |
| BLUMENKRANZ MARK S | Director | Stock Award(Grant) | Jun 10, 2024 | 182,821 |
| BRAZZELL ROMULUS KIM | Officer | Sale | Jun 25, 2024 | 83,982 |
| IWICKI MARK T. | Chief Executive Officer | Sale | Jun 25, 2024 | 263,755 |
| KHARABI DARIUS | Officer | Sale | Jun 25, 2024 | 59,728 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 10, 2024 | 13,922 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 19.33% | 891,335 | 5.35M | Sep 29, 2024 |
| SR One Capital Management, LP | 9.62% | 443,661 | 2.66M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 6.64% | 306,067 | 1.84M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 3.53% | 162,663 | 975.98K | Sep 29, 2024 |
| Millennium Management Llc | 3.05% | 140,731 | 844.39K | Sep 29, 2024 |
| Vanguard Group Inc | 1.16% | 53,570 | 321.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.57% | 26,442 | 158.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.57% | 26,296 | 157.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 20,825 | 124.95K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 8,351 | 50.11K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 4,997 | 29.98K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,482 | 8.89K | Oct 30, 2024 |